FDA Requests Comments for ICCR-20 in Tokyo

The US Food and Drug Administration (FDA) is seeking comments from the public on various topics pertaining cosmetics regulations as it prepares for the next annual meeting of the International Cooperation on Cosmetics Regulation. That meeting (ICCR-20) is scheduled for July 7-9, 2026 in Tokyo.

 ICCR is a voluntary international group of cosmetics regulatory authorities, including the FDA, that meets on an annual basis to discuss common issues cosmetics safety and regulation, and enter into constructive dialogue with relevant cosmetics industry trade associations.

Electronic or written comments must be submitted by May 18, according to the Agency.

ICCR Multilateral Framework

The intention of ICCR multilateral framework is to pave the way for the removal of regulatory obstacles to international trade while maintaining global consumer protection.

ICCR members will engage in dialogue with their relevant cosmetics industry trade associations and other interested parties.

Current ICCR members include regulatory authorities from Brazil, Canada, Chinese Taipei, the European Union, Israel, Japan, Republic of Korea and the US.

ICCR-19 Meeting

The last gathering, ICCR-19, was held in Ottawa, Canada in July 2025. At ICCR-19 representatives from Cape Verde, Egypt, People’s Republic of China, Saudi Arabia, Thailand and the United Kingdom participated in the meeting as observers, according to the meeting report.

FDA’s Request for Comments for ICCR-20

ICCR considers various topics of common interest and relevance for cosmetics.

FDA is requesting public comment on the following questions related to topics identified for the ICCR-20 meeting. FDA is also requesting public comment on any additional cosmetics topics of interest for consideration by ICCR for future work.

• What new International Organization for Standardization (ISO) standards and technical reports should be considered for inclusion in the Updated Annex of International Standards in Cosmetics Report?
• What new non-animal testing methods should be considered for inclusion in the Inventory of Validated Non-Animal Testing Methods Applicable for Cosmetic Products and their Ingredients in all ICCR Regions?
• What are your suggestions to help make risk assessment using non-animal data a more common approach for safety assessments of cosmetic ingredients?
• What general principles should be considered for electronic labeling (e-labeling) and digital information for cosmetics across ICCR member jurisdictions?
• What are common questions and misconceptions and ways to improve understanding related to cosmetics use, safety, and regulation that arise across ICCR member jurisdictions?
• What are your suggestions for any changes to or considerations for ICCR’s purpose, mission and future direction?

Additional information from FDA can be access here. Information about ICCR can be found here.